General Comments / Chat, page-5429

It could be worthwhile to add some revenue or market size metrics to your summary ... ?

Some stats to get started. I couldn't find annual revenue stats for everything, however did find an interesting partnership!

Decetabine

Dacogen (Decetabine) peak sales USD $250M

https://pink.pharmaintelligence.inf...n-Peak-Sales-Of-250-Mil-Action-Date-Is-Sept-1


Clofarabine

Clofarabine moving annual sales 2017 USD $53M

https://www.business-standard.com/a...-cancer-drug-in-us-market-117111400575_1.html


lenvatinib

Merck & Co., Eisai in Oncology Pact Worth Up to $5.76 Billion

Under the agreement, Merck will pay Eisai an upfront payment of $300 million, up to $650 million for certain option rights through 2020, and $450 million as reimbursement for research and development expenses. In addition, Eisai is eligible to receive up to $385 million associated with the achievement of certain clinical and regulatory milestones and a maximum of up to $3.97 billion for the achievement of milestones associated with sales of Lenvima.

https://www.biopharminternational.com/view/merck-co-eisai-oncology-pact-worth-576-billion

FDA Approves LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) Combination for First-Line Treatment of Adult Patients With Advanced Renal Cell Carcinoma (RCC)

https://www.eisai.com/news/2021/news202169.html

Cabozantinib

Cabozantinib Franchise Net Product Revenues and Royalties.
For the year ended December 31, 2020 , net product revenues generated by the cabozantinib franchise in the U.S. were $741.6 million , with net product revenues of $718.7 million from CABOMETYX and $22.9 million from COMETRIQ.

https://ir.exelixis.com/news-releas...s-fourth-quarter-and-full-year-2020-financial

Carfilzomib

Kyprolis (Carfilzomib) annual sales USD $1.065B

https://www.amgen.com/newsroom/pres...-quarter-and-full-year-2021-financial-results

Anti-PD1 market

For 2020 USD $23B

https://www.fiercepharma.com/pharma...ckers-cancer-grow-pan-adjuvant-use-key-report